The goal of the study was to establish a rapid method for the quantification of osimertinib in plasma from patients treated for NSCLC with EGFR mutation using MALDI–IM–MS/MS and to validate it according to the guidelines of the FDA and EMA for bioanalytical method validation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.